View in EDS

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Saved in:
Bibliographic Details
Title: A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
Authors: Brunner AM; Massachusetts General Hospital, Boston, Massachusetts, United States., Liu Y; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Garcia JS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Mendez LM; Yale University School of Medicine, New Haven, Connecticut, United States., Gutierrez C; Dana-Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts, United States., Nonavinkere Srivatsan S; Washington University St Louis, Saint Louis, Missouri, United States., Shao J; Washington University School of Medicine, St. Louis, Missouri, United States., Aubrey BJ; Massachusetts General Hospital, United States., Amrein PC; Massachusetts General Hospital, Boston, Massachusetts, United States., Narayan R; Massachusetts General Hospital, Boston, Massachusetts, United States., Vedula RS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Friedman E; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Neuberg DS; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Andrade Campos M; AstraZeneca, Barcelona, Spain., Smith SA; AstraZeneca, Cambridge, United Kingdom., Stone RM; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Fathi AT; Massachusetts General Hospital / Harvard Medical School, Boston, Massachusetts, United States., Walter MJ; Washington University School of Medicine, St. Louis, Missouri, United States., Graubert TA; Massachusetts General Hospital, Boston, Massachusetts, United States., Jacoby MA; Washington University School of Medicine, St. Louis, Missouri, United States.
Source: Blood advances [Blood Adv] 2026 Jun 30. Date of Electronic Publication: 2026 Jun 30.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2026019848